Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 163 of 163 results for metastatic breast cancer

  1. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    Awaiting development [GID-TA11273] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    Awaiting development [GID-TA11342] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990

    Awaiting development [GID-TA11519] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update): draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 19 April 2024.

    NICE guideline
    In consultation

  5. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370

    In development [GID-TA11513] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer TS ID 12010

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development [GID-TA11487] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]

    In development [GID-TA10813] Expected publication date: 15 May 2024

    Technology appraisal guidance
    In development

  9. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

    In development [GID-NG10419] Expected publication date: 31 March 2025

    NICE guideline
    In development

  11. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development